Search Within

Gilles Andre Salles

Formats
  1. Meeting Abstract (181)
  2. Journal Article (74)
  3. Research Letter (18)
  4. Review (16)
  5. Editorial (5)
  6. Correspondence (3)
  7. Conference Paper (2)
  8. Guidelines (2)
  9. Book Section (1)
Groups
  1. Department of Medicine (302)
  2. Hematologic Malignancies, Division of (302)
  3. Center for Hematologic Malignancies (163)
  4. Lymphoma (159)
  5. Survivorship Research (115)
  6. Graduate Medical Education (106)

More Groups

People
  1. Maria Palomba (108)
  2. Andrew Zelenetz (74)
  3. Lorenzo Falchi (64)
  4. Anita Kumar (63)
  5. Gunjan Shah (61)
  6. Miguel-Angel Perales (59)

More People

Years
  1. 2025 (19)
  2. 2024 (67)
  3. 2023 (97)
  4. 2022 (69)
  5. 2021 (44)
  6. 2020 (6)
Publications
  1. Blood (126)
  2. Hematological Oncology (28)
  3. Journal of Clinical Oncology (17)
  4. Blood Advances (16)
  5. Haematologica (14)
  6. British Journal of Haematology (9)

More Publications

Publishers
  1. American Society of Hematology (143)
  2. Wiley Blackwell (30)
  3. Elsevier Inc. (20)
  4. American Society of Clinical Oncology (17)
  5. Ferrata Storti Foundation (14)
  6. Nature Publishing Group (14)

More Publishers

Results (302)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Role of maintenance rituximab after first‐line bendamustine + rituximab or R‐CHOP in patients with mantle cell lymphoma from a large US real‐world cohort
    Meeting Abstract

    Wang, M.; Salles, G.; Kumar, A.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Martin, P.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Real‐world treatment patterns and outcomes of 3455 previously untreated mantle cell lymphoma patients in US routine clinical practice
    Meeting Abstract

    Kumar, A.; Martin, P.; Wang, M.; Qi, K.; Daly, K.; Parisi, L.; Zhu, A.; Salles, G.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Estimation of long‐term survival with tafasitamab + lenalidomide (LEN) in relapsed/refractory diffuse large B‐cell lymphoma (R/R DLBCL)
    Meeting Abstract

    Salles, G.; Goswami, B.; Bagnardi, V.; Dey, D.; Winderlich, M.; Ambarkhane, S.; Huang, D.; Nowakowski, G. S.
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Circulating tumor DNA load and total metabolic tumor volume in diffuse large B cell lymphoma (DLBCL) patients treated by R‐CHOP – From REMARC, a LYSA study
    Meeting Abstract

    Bohers, E.; Delfau‐Larue, M.; Vercellino, L.; Cottereau, A.; Viennot, M.; Viailly, P.; Salles, G.; Tilly, H.; Damaj, G.; Haioun, C.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Clinical outcomes and the role of observation in early‐stage follicular lymphoma
    Meeting Abstract

    Sha, F.; Okwali, M.; Alperovich, A.; Caron, P. C.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Kumar, A.; more...
    Hematological Oncology (2021)

    Fulltext@MSK | Save
  • Indirect treatment comparison of liso-cel vs. salvage chemotherapy in diffuse large B-cell lymphoma: TRANSCEND vs. SCHOLAR-1
    Journal Article

    Salles, G.; Spin, P.; Liu, F. F.; Garcia, J.; Kim, Y.; Hasskarl, J.
    Advances in Therapy (2021)

    Fulltext@MSK | Save
  • The role of tazemetostat in relapsed/refractory follicular lymphoma
    Review

    von Keudell, G.; Salles, G.
    Therapeutic Advances in Hematology (2021)

    Fulltext@MSK | Save
  • Diffuse large B-cell lymphoma - Reply
    Correspondence

    Sehn, L. H.; Salles, G.
    New England Journal of Medicine (2021)

    Fulltext@MSK | Save
  • Optimizing CAR T cell therapy in lymphoma
    Conference Paper

    Qualls, D.; Salles, G.
    Wiley Blackwell (2021)

    Fulltext@MSK | Save
  • EZH2 inhibition by tazemetostat: Mechanisms of action, safety and efficacy in relapsed/refractory follicular lymphoma
    Review

    Julia, E.; Salles, G.
    Future Oncology (2021)

    Fulltext@MSK | Save